Proteasome Inhibitors Market Size Worth $1.7 Billion by 2023
Key suggestions from the report:
- VELCADE segment represented more than 54% of the overall volume in 2018 owing to the advances in the research that helps the drug capture new patient pools.
- KYPROLIS segment is likely to register a CAGR of more than 10% in terms of revenue from 2019 to 2023 on account of the superior efficacy and the target affinity of KYPROLIS.
- NINLARO commanded over 11% of proteasome inhibitors volume share in 2018 and is expected to witness considerable growth during the forecast period, owing to diverse research being conducted on the drug.
- The North-American proteasome inhibitors market accounted for about close to 47% of the overall revenue in 2018, owing to the growing prevalence of various cancer indications including multiple myeloma and non-Hodgkin’s lymphoma.
- The proteasome inhibitors market is moderately concentrated with a few players occupying the market share. The market is witnessing an increasing collaboration between vendors that will considerably reduce the market competition among vendors.
The
market has only a limited number of approved therapies for multiple
myeloma, with three branded proteasome inhibitors and one generic
proteasome inhibitors approved. This has created opportunities for
vendors to develop new proteasome inhibitors for the treatment of
multiple myeloma. Thus, the huge unmet need is expected to attract
various pharmaceutical vendors to conduct studies and launch the
product, which will fuel the growth of the proteasome inhibitors market
during the forecast period.
Proteasome
inhibitors have long been developed for the treatment of blood cancer
indications, with a focus on multiple myeloma. However, vendors are
conducting studies on these drugs for the treatment of solid tumors
also, which has led to the pipeline for proteasome inhibitors consisting
of various molecules under investigation for solid tumors. It is also
being developed for malignant melanoma, neuroblastoma, and pancreatic
cancer. Thus, the expanded application of proteasome inhibitors is
expected to fuel the growth of the market.
Comments
Post a Comment